These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 31605014)

  • 1. VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR-PI3K-AKT pathway.
    Zhangyuan G; Wang F; Zhang H; Jiang R; Tao X; Yu D; Jin K; Yu W; Liu Y; Yin Y; Shen J; Xu Q; Zhang W; Sun B
    Oncogene; 2020 Feb; 39(6):1213-1230. PubMed ID: 31605014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.
    Wang Z; Qu L; Deng B; Sun X; Wu S; Liao J; Fan J; Peng Z
    Sci Rep; 2016 Sep; 6():33205. PubMed ID: 27628214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NCSTN promotes hepatocellular carcinoma cell growth and metastasis via β-catenin activation in a Notch1/AKT dependent manner.
    Li H; Lan T; Xu L; Liu H; Wang J; Li J; Chen X; Huang J; Li X; Yuan K; Zeng Y; Wu H
    J Exp Clin Cancer Res; 2020 Jul; 39(1):128. PubMed ID: 32631394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MEG2 inhibits the growth and metastasis of hepatocellular carcinoma by inhibiting AKT pathway.
    Ying D; Ruan Y; Zhou X
    Gene; 2019 Mar; 687():1-8. PubMed ID: 30399427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway.
    Fu X; Wen H; Jing L; Yang Y; Wang W; Liang X; Nan K; Yao Y; Tian T
    Cancer Sci; 2017 Apr; 108(4):620-631. PubMed ID: 28132399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FAM9C plays an anti-apoptotic role through activation of the PI3K/Akt pathway in human hepatocellular carcinoma.
    Zhou JD; Shen F; Ji JS; Zheng K; Huang M; Wu JC
    Oncol Rep; 2013 Sep; 30(3):1275-84. PubMed ID: 23836295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HHLA2 promotes hepatoma cell proliferation, migration, and invasion via SPP1/PI3K/AKT signaling pathway.
    Wang J; Yang K; Yang X; Jin T; Tian Y; Dai C; Xu F
    Mol Carcinog; 2024 Jul; 63(7):1275-1287. PubMed ID: 38578157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis.
    Ma XL; Shen MN; Hu B; Wang BL; Yang WJ; Lv LH; Wang H; Zhou Y; Jin AL; Sun YF; Zhang CY; Qiu SJ; Pan BS; Zhou J; Fan J; Yang XR; Guo W
    J Hematol Oncol; 2019 Apr; 12(1):37. PubMed ID: 30971294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.
    Chen H; Wong CC; Liu D; Go MYY; Wu B; Peng S; Kuang M; Wong N; Yu J
    Theranostics; 2019; 9(18):5246-5260. PubMed ID: 31410213
    [No Abstract]   [Full Text] [Related]  

  • 10. Cleavage and polyadenylation-specific factor 3 induces cell cycle arrest via PI3K/Akt/GSK-3β signaling pathways and predicts a negative prognosis in hepatocellular carcinoma.
    Li N; Jiang S; Fu R; Lv J; Yao J; Mai J; Hua X; Chen H; Liu J; Lu M
    Biomark Med; 2021 Apr; 15(5):347-358. PubMed ID: 33666519
    [No Abstract]   [Full Text] [Related]  

  • 11. T-lymphoma invasion and metastasis 1 promotes invadopodia formation and is regulated by the PI3K/Akt signaling pathway in hepatocellular carcinoma.
    Wang B; Zheng B; Cao L; Liao K; Huang D; Zhang Y; Jiang Y; Zheng S
    Exp Cell Res; 2021 Oct; 407(2):112806. PubMed ID: 34487727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERCC6L promotes the progression of hepatocellular carcinoma through activating PI3K/AKT and NF-κB signaling pathway.
    Chen H; Wang H; Yu X; Zhou S; Zhang Y; Wang Z; Huang S; Wang Z
    BMC Cancer; 2020 Sep; 20(1):853. PubMed ID: 32891122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Forkhead box Q1 promotes hepatocellular carcinoma metastasis by transactivating ZEB2 and VersicanV1 expression.
    Xia L; Huang W; Tian D; Zhang L; Qi X; Chen Z; Shang X; Nie Y; Wu K
    Hepatology; 2014 Mar; 59(3):958-73. PubMed ID: 24005989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epithelial V-like antigen 1 promotes hepatocellular carcinoma growth and metastasis via the ERBB-PI3K-AKT pathway.
    Ni Q; Chen Z; Zheng Q; Xie D; Li JJ; Cheng S; Ma X
    Cancer Sci; 2020 May; 111(5):1500-1513. PubMed ID: 31997489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AURKB targets DHX9 to promote hepatocellular carcinoma progression via PI3K/AKT/mTOR pathway.
    Zhu G; Luo L; He Y; Xiao Y; Cai Z; Tong W; Deng W; Xie J; Zhong Y; Hu Z; Shan R
    Mol Carcinog; 2024 Sep; 63(9):1814-1826. PubMed ID: 38874176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma.
    Huang JL; Cao SW; Ou QS; Yang B; Zheng SH; Tang J; Chen J; Hu YW; Zheng L; Wang Q
    Mol Cancer; 2018 May; 17(1):93. PubMed ID: 29803224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EVA1A reverses lenvatinib resistance in hepatocellular carcinoma through regulating PI3K/AKT/p53 signaling axis.
    Liu X; Gao X; Yang Y; Yang D; Guo Q; Li L; Liu S; Cong W; Lu S; Hou L; Wang B; Li N
    Apoptosis; 2024 Aug; 29(7-8):1161-1184. PubMed ID: 38743191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KDM5A silencing transcriptionally suppresses the FXYD3-PI3K/AKT axis to inhibit angiogenesis in hepatocellular cancer via miR-433 up-regulation.
    Ma YS; Wu TM; Qian B; Liu YS; Ding H; Fan MM; Liu JB; Yu F; Wang HM; Shi Y; Gu LP; Li L; Tian LL; Wang PY; Wang GR; Wu ZJ; Zou QF; Ling CC; Fu D
    J Cell Mol Med; 2021 Apr; 25(8):4040-4052. PubMed ID: 33621431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma.
    Liu J; Zhang C; Lin M; Zhu W; Liang Y; Hong X; Zhao Y; Young KH; Hu W; Feng Z
    Oncotarget; 2014 May; 5(9):2635-47. PubMed ID: 24797434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long noncoding RNA LEF1-AS1 acts as a microRNA-10a-5p regulator to enhance MSI1 expression and promote chemoresistance in hepatocellular carcinoma cells through activating AKT signaling pathway.
    Gao J; Dai C; Yu X; Yin XB; Zhou F
    J Cell Biochem; 2021 Jan; 122(1):86-99. PubMed ID: 32786108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.